Filing Flows › Nurix Therapeutics (NRIX) › Q2 FY26 › vs Q1 FY26
Nurix Therapeutics (NRIX) Q2 FY26 vs Q1 FY26 (quarter over quarter)
Nurix Therapeutics's revenue rose $2.8M (+45%) from $6.3M in Q1 FY26 to $9.0M in Q2 FY26.
Nurix Therapeutics, Q2 FY26: revenue $9.0M (-80% year over year), net loss $89.5M, operating cash flow −$96.6M. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q2 FY26 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $9.0M | $6.3M | $2.8M | +45% |
| Other income, net | $4.4M | $5.3M | −$923K | -17% |
| Income tax benefit | $271K | $0 | $271K | — |
| Net loss | $89.5M | $87.2M | $2.4M | +3% |
| Costs & expenses | $103M | $98.7M | $4.5M | +5% |
| Operating costs | $103M | $98.7M | $4.5M | +5% |
| Research & development | $87.7M | $84.1M | $3.5M | +4% |
| General & admin | $15.6M | $14.6M | $984K | +7% |
| Operating cash sources | $110M | $83.5M | $26.7M | +32% |
| Depreciation & amortization | $2.3M | $2.2M | $59K | +3% |
| Share-based compensation | $11.4M | $9.4M | $2.0M | +21% |
| Cash used in operations | $96.6M | $71.9M | $24.7M | +34% |
| Net loss absorbed | $89.5M | $87.2M | $2.4M | +3% |
| Working capital & other | $20.7M | −$3.7M | $24.3M | — |
Questions
How much did Nurix Therapeutics's revenue grow quarter over quarter in Q2 FY26?
Nurix Therapeutics's revenue rose $2.8M (+45%) from $6.3M in Q1 FY26 to $9.0M in Q2 FY26.